Who
Shawn Olsson
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, LENZ Therapeutics.
In numbers
- Trades disclosed
- 17
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $261K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 21 Mar 2024
- Last trade
- 2 Jan 2026
- Last filed
- 6 Jan 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 6 Jan 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,200 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,200 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 17 Nov 2025filed 19 Nov 2025 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 17 Nov 2025filed 19 Nov 2025 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Code M | $21K10,000 at $2.08 | filing |
| 17 Nov 2025filed 19 Nov 2025 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K4,212 at $25.74 | filing |
| 17 Nov 2025filed 19 Nov 2025 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Sold | $153K5,788 at $26.37 | filing |
| 9 Apr 2025filed 9 Apr 2025 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,400 at $0.00 | filing |
| 9 Apr 2025filed 9 Apr 2025 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,9121,400 at $2.08 | filing |
| 9 Jan 2025filed 13 Jan 2025 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,100 at $0.00 | filing |
| 16 Dec 2024filed 17 Dec 2024 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,333 at $0.00 | filing |
| 16 Dec 2024filed 17 Dec 2024 | LENZ LENZ TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,9333,333 at $2.08 | filing |
| 21 Mar 2024filed 25 Mar 2024 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,974 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,466 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,915 at $0.00 | filing |
| 21 Mar 2024filed 25 Mar 2024 | LENZ LENZ Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
News
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Stock Has Average Target Price of $28.80LENZ · dailypolitical.com · 20 Oct 2026
0 headlines in the last 90 days name Shawn Olsson; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.